Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 107980
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.107980
Table 5 Comparison of features between the training and validation sets, n (%)
Characteristic
Test (n = 78)
Train (n = 182)
χ2
P value
Age, years0.800.370
    < 6039 (50.00)80 (43.96)
    ≥ 6039 (50.00)102 (56.04)
Sex0.210.645
    Female37 (47.44)92 (50.55)
    Male41 (52.56)90 (49.45)
BMI, kg/m20.210.054
    < 2566 (84.62)134 (73.63)
    ≥ 2512 (15.38)48 (26.37)
FAR0.620.432
    Low34 (43.59)89 (48.90)
    High44 (56.41)93 (51.10)
ECOG0.210.647
    050 (64.10)122 (67.03)
    128 (35.90)60 (32.97)
Site0.870.350
    Stomach42 (53.85)86 (47.25)
    Gastric and esophageal binding36 (46.15)96 (52.75)
Histological1.740.188
    Adenocarcinoma25 (32.05)44 (24.18)
    Other53 (67.95)138 (75.82)
Staging0.770.379
    327 (36.62)53 (29.12)
    451 (65.38)129 (70.88)
CEA, ng/mL3.600.058
    < 339 (50.00)68 (37.36)
    ≥ 339 (50.00)114 (62.64)
Liver metastasis0.590.441
    No54 (69.23)114 (64.29)
    Yes24 (30.77)68 (37.36)
Peritoneal metastasis1.040.308
    No61 (78.21)152 (83.52)
    Yes17 (21.97)30 (16.48)
EBV status0.000.971
    No-infect65 (83.33)152 (83.52)
    Infect13 (16.67)30 (16.48)
PD-L1 expression0.290.588
    CPS < 514 (17.95)38 (4.40)
    CPS ≥ 564 (82.05)174 (95.60)
MMR status0.001.000
    pMMR4 (5.13)8 (4.40)
    dMMR74 (94.87)174 (95.60)